The antidepressant treatment response index and treatment outcomes in a placebo-controlled trial of fluoxetine

Journal of Clinical Neurophysiology

Volumn 28, Issue 5, 2011, Pages 478-482

  Hunter, Aimee M ^a,b   Cook, Ian A ^a,b   Greenwald, Scott D ^c   Tran, Melody L ^a,b   Miyamoto, Kate N ^a,b   Leuchter, Andrew F ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Aspect Medical Systems   (United States)

Author keywords

Antidepressant medication; Biomarker; EEG; Placebo response

Indexed keywords

FLUOXETINE; PLACEBO;

ADULT; ANTIDEPRESSANT TREATMENT RESPONSE INDEX; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; ELECTROENCEPHALOGRAPHY; FEMALE; HAMILTON SCALE; HUMAN; MAJOR DEPRESSION; MALE; PREDICTIVE VALUE; PREMEDICATION; RANDOMIZED CONTROLLED TRIAL; REMISSION; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SINGLE BLIND PROCEDURE; SYMPTOM; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CHI-SQUARE DISTRIBUTION; DEPRESSIVE DISORDER, MAJOR; ELECTROENCEPHALOGRAPHY; FEMALE; FLUOXETINE; HUMANS; LOS ANGELES; MALE; MIDDLE AGED; PLACEBOS; PREDICTIVE VALUE OF TESTS; PSYCHIATRIC STATUS RATING SCALES; REMISSION INDUCTION; ROC CURVE; SENSITIVITY AND SPECIFICITY; SEROTONIN UPTAKE INHIBITORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 80053605509     PISSN: 07360258     EISSN: 15371603     Source Type: Journal    
DOI: 10.1097/WNP.0b013e318230da8a     Document Type: Article

References (14)

1. Bauer M, Bschor T, Pfennig A, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders in primary care. World J Biol Psychiatry 2007;8: 67-104. (Pubitemid 46690921)
2. Cook IA, Leuchter AF, Morgan M, et al. Early changes in prefrontal activity characterize clinical responders to antidepressants. Neuropsychopharmacology 2002;27:120-131. (Pubitemid 34626748)
3. Hunter AM, Cook IA, Leuchter AF. The promise of the quantitative electroencephalogram as a predictor of antidepressant treatment outcomes in major depressive disorder. Psychiatr Clin North Am 2007;30:105-124. (Pubitemid 46394587)
4. Insel TR, Wang PS. The STAR*D trial: revealing the need for better treatments. Psychiatr Serv 2009;60:1466-1467.
5. Iosifescu DV, Greenwald SD, Smith CP, et al. Frontal EEG at week 1 predicts clinical response to SSRI treatment in MDD. Poster (#231) presented at: Annual Meeting of the American Psychiatric Association; May 22, 2006; Toronto, Canada.
6. Iosifescu DV, Greenwald S, Devlin P, et al. Frontal EEG predictors of treatment outcome in major depressive disorder. Eur Neuropsychopharmacol 2009;19: 772-777.
7. Leuchter AF, Cook IA, Witte EA, et al. Changes in brain function of depressed subjects during treatment with placebo. Am J Psychiatry 2002;159: 122-129. (Pubitemid 41070737)
8. Leuchter AF, Cook IA, Marangell LB, et al. Comparative effectiveness of bio-markers and clinical indicators for predicting outcomes of SSRI treatment in major depressive disorder: results of the BRITE-MD study. Psychiatry Res 2009a;169:124-131.
9. Leuchter AF, Cook IA, Gilmer WS, et al. Effectiveness of a quantitative electro-encephalographic biomarker for predicting differential response or remission with escitalopram and bupropion in major depressive disorder. Psychiatry Res 2009b;169:132-138.
10. Leuchter AF, Cook IA, Hunter AM, Korb AS. A new paradigm for the prediction of antidepressant treatment response. Dialogues Clin Neurosci 2009c;11:435-446.
11. Mayberg HS, Silva JA, Brannan SK, et al. The functional neuroanatomy of the placebo effect. Am J Psychiatry 2002;159:728-737. (Pubitemid 34465045)
12. Poland R, Greenwald SD, Smith CP, et al. Frontal EEG at 1 week predicts response to treatment with citalopram in MDD. Poster presented at: Annual Meeting of the American Psychiatric Association; May 22, 2006; Toronto, Canada.
13. Quitkin FM, Petkova E, McGrath PJ, et al. When should a trial of fluoxetine for major depression be declared failed?. Am J Psychiatry 2003;160: 734-740. (Pubitemid 41079607)
14. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalo-pram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006;163:28-40. (Pubitemid 43050100)